HRCT scan. Then, they were clinically and radiologically diagnosed as having interstitial lung disease (ILD), IIP or connective tissue diseases associated ILD were enrolled. We applied IPAF criteria to these patients. Then, we purified 68 patients. The prognostic factors for exacerbation were prospectively calculated and statistically analyzed using clinical, laboratory and imaging data collected from medical records.

Results: Prevalence of IPAF was 10.1%. Of 68 patients with IPAF, 60% were women and mean age at diagnosis was 64.2 ± 13.8 years old. Mean observation period was 27.1 ± 29.6 months. Smoking history was 42.6% (n=29). Treatment including oral glucocorticoid or/and immunosuppressant use were 44.1% (n=30). Exacerbation rate was 25% (n=17). Overall death rate was 5.9% (n=4) and respiratory death rate was 2.9% (n=2). Comparison of characteristics at diagnosis between the exacerbation group and non-exacerbation group showed that the exacerbation group had a significantly elevated rate of smoking history, KL-6, and SP-D ($P=0.01$, 0.006, and 0.03, respectively). We then analyzed transition of KL-6 in patients with IPAF, IIP, or CTD-ILD. KL-6 at baseline in patients with IPAF (1212 ± 1626 U/mL) was higher than those with IIP and significantly higher than those with CTD-ILD (1030 ± 1027 U/mL ($P=0.69$) and 829.5 ± 1002 U/mL ($P=0.024$)), while exacerbation rate in patients with IPAF (25%) was significantly lower than those in IIP patients (40%) and CTD-ILD patients (41%) ($P=0.03$). Furthermore, KL-6 in IPAF patients gradually decreased during course and was lower than IIP or CTD-ILD patients at 84 months from diagnosis.

Conclusion: Our large-scale observational cohort study revealed prevalence of IPAF in patients with ILD and identified three baseline factors associated with exacerbation in the patients with IPAF and suggested that IPAF might have a better prognosis than IIP or CTD-ILD.

REFERENCES:

- [1] Respir Med. 2017; 123:56–62,
- [2] Eur Respir J. 2016; 47:1622–1624,
- [3] Clin Rheumatol. 2018 Apr 18

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.5275

THU0678

MALIGNANCY RISK IN MALE PATIENTS WITH ANKYLOSING SPONDYLITIS

Bora Nam¹, Hyoungyoung Kim¹, Eun Jin Jang², Soo-Kyung Cho¹, Yoon-Kyoung Sung¹, Tae-Hwan Kim¹. ¹Hanyang University Hospital for Rheumatic Diseases, Department of Rheumatology, Seoul, Korea, Rep. of (South Korea); ²Andong National University, Department of Information Statistics, Andong, Korea, Rep. of (South Korea)

Background: In recent studies, the association between autoimmune disease and malignancy has been reported. However in Ankylosing spondylitis (AS), a chronic inflammatory rheumatic disease with marked male predominance, the evidence of this relationship is scarce and inconsistent.

Objectives: To determine the overall cancer and site-specific cancer risk in male patients with AS.

Methods: Using the claims database of Health Insurance and Review Assessment (HIRA), male patients with AS without prior cancer history between 2012 and 2014 were enrolled (n=21,780). For the control group, male general population, stratified random samples of claims data were used (n=342,361). All individual was observed up to the development of any cancer, or end of the study period (December 31, 2015). Incidence rates (IR) of overall and site-specific cancer were presented as the number of event per 10,000 person-years. To make fairer comparison between AS patients and general population, we calculated age adjusted incidence ratio by dividing cancer event of general population with corresponding age. The standardized incidence ratio (SIR) was used to represent the association between AS and cancer, accounting for person-years at risk.

Results: During 71,046 person-year, total 552 cases of cancer occurred in male AS group. Prostate cancer was the leading type of cancer in male AS patients (101 cases, IR 14.22, 95% CI 11.44-16.99). And it was followed by liver cancer (70 cases, IR 9.9, 95% CI 7.5-12.2), lung cancer (48 cases, IR 6.8, 95% CI 4.9-8.7), colorectal cancer (45 cases, IR 6.3, 95% CI 4.5-8.2) and stomach cancer (43 cases, IR 6.1, 95% CI 4.2-7.9). Compared to general population, the overall incidence of cancer was increased in male patients with AS (SIR 1.25, 95% CI 1.14-1.36).

At a specific malignancy type, the risk of pancreas cancer (SIR 1.75, 95% CI 1.12-2.37) and malignancy of male reproductive system were increased (SIR 1.97, 95% CI 1.59-2.35).

Table 1. The standardized incidence ratio of overall malignancy.

Type of Malignancy	Male general population	Male AS patients		SIR (95% CI)
	IR (95% CI)	Age-adjusted expected IR (95% CI)	IR (95% CI)	
All malignancy	102.5 (100.7-104.3)	65.0 (63.7-66.2)	77.7 (71.2-84.2)	1.25 (1.14-1.36)
Hematologic malignancy	3.4 (3.0-3.7)	2.3 (2.1-2.6)	3.8 (2.4-5.2)	1.69 (1.06-2.34)
Solid malignancy	99.1 (97.4-100.9)	62.6 (61.4-63.9)	73.9 (67.6-80.2)	1.24 (1.13-1.34)

Incidence rate was presented as the number of events per 10,000 person-year with 95% CI
AS, ankylosing spondylitis; IR, incidence ratio; SIR, standardized incidence ratio; CI, confidence interval

Figure 1. The standardized incidence ratio of hematologic malignancy.

Figure 2. The standardized incidence ratio of solid cancer.

Conclusion: Male patients with AS have a increased overall cancer risk, especially in pancreas cancer and malignancy of male reproductive system.

REFERENCES:

- [1] Deng, C. et al., Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep, 2016. 6: p. 32063.
- [2] Egiziano, G. et al., Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol, 2016. 30(1): p. 53-62.

Disclosure of Interests: Bora Nam: None declared, Hyoungyoung Kim: None declared, Eun Jin Jang: None declared, Soo-Kyung Cho: None declared, Yoon-Kyoung Sung Grant/research support from: Dr. Yoon-Kyoung, Sung has received research funding from BMS, Eisai, Pfizer, JW pharmaceutical., Consultant for: Dr. Yoon-Kyoung, Sung has served as a consultant to AbbVie and Amgen, Speakers bureau: Dr. Yoon-Kyoung, Sung has received honoraria from AbbVie, Amgen, BMS, Pfizer., Tae-hwan Kim: None declared

DOI: 10.1136/annrheumdis-2019-eular.6555

THU0679

ADHERENCE TO THE MEDITERRANEAN DIET AND RISK OF RHEUMATOID ARTHRITIS IN THE FRENCH PROSPECTIVE E3N COHORT STUDY

Yann Nguyen^{1,2}, Carine Salliot^{1,3}, Amandine Gelot¹, Juliette Gambaretti¹, Xavier Mariette^{2,4}, Marie-Christine Boutron-Ruault¹, Raphaële Seror^{2,4}. ¹Center for Research in Epidemiology and Population Health – INSERM U1018 – Université Paris Saclay – Université Paris Sud, Villejuif, France; ²AP-HP Hôpital Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France; ³Centre Hospitalier Régional d'Orléans, Rheumatology, Orléans, France; ⁴Université Paris-Sud, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), INSERM UMR 1184, Université Paris-Saclay, Le Kremlin-Bicêtre, France

Background: The Mediterranean diet (MD), widespread in Southern European countries, mainly consists of olive oil, cereal products, fresh or dried fruit and vegetables, nuts, a moderate amount of dairy and meat, and many condiments and spices. It has been associated with significant reduction of overall mortality, cardiovascular diseases, and neoplastic diseases. It has been suggested to have a beneficial effect on rheumatoid arthritis (RA) activity due to its richness in antioxidants and unsaturated fatty acids. However, data on MD as a prevention of RA are limited.

Objectives: To assess the association between adherence to MD and risk of RA in a general population cohort.

Methods: The E3N cohort study (*Etude Epidémiologique auprès des femmes de la Mutuelle générale de l'Education Nationale*) is a French prospective cohort of 98,995 healthy women included in 1990-91 and followed since then (median follow-up of 28 years). Among women who completed a food-frequency questionnaire, we calculated the modified MD score (from 0 to 9) according to the consumption status of nine food components. Incident RA cases were detected using a validation process using a specific validation questionnaire and a drug reimbursement database. Hazard ratios (HRs) and 95% confidence intervals (CIs) for incident RA were estimated using Cox proportional hazards regression models with age as the time scale, and adjusting for known risk factors of RA and potential confounders. Because of the known importance of smoking on RA risk, we performed analyses adjusted and stratified on the smoking status.

Results: Among 62,630 women, 480 validated incident RA cases were diagnosed after a mean ($\pm$ standard deviation) of 11.7 ($\pm$ 5.9) years after the food-frequency questionnaire. In the whole population, high adherence to MD was not associated with a decreased risk of RA (HR for a 6-9 vs. 0-3 score = 0.86, 95% CI: 0.68–1.09, $P_{\text{linear trend}}$ = 0.11). However, among ever-smoking women (current or past smokers), high adherence to MD was associated with a decreased risk of RA (HR for a 6-9 vs. 0-3 score = 0.77, 95% CI: 0.53–1.05; $P_{\text{linear trend}}$ = 0.025), while there was no association in non-smokers (HR for a 6-9 vs. 0-3 score = 0.98, 95% CI: 0.70–1.38, $P_{\text{linear trend}}$ = 0.90).

HR (95% IC) for RA according to the MD score

MD score	[0-3]	[4-5]	[6-9]	P for trend
All population (N = 62,630)				
Cases no./person-years, no.	152/372,306	211/575,893	118/325,196	
Age adjusted	1	0.89 (0.72-1.10)	0.86 (0.68-1.09)	0.11
Multivariate*	1	0.89 (0.72-1.10)	0.86 (0.67-1.10)	0.1098
Ever smokers (N = 29,072)				
Cases no./person-years, no.	73/165,745	101/270,722	57/154,709	
Age adjusted	1	0.78 (0.58-1.04)	0.74 (0.53-1.05)	0.0247
Multivariate*	1	0.79 (0.58-1.06)	0.77 (0.54-1.09)	0.0444
Non smokers (N = 33,558)				
Cases no./person-years, no.	73/206,562	110/305,171	61/170,488	
Age adjusted	1	1.01 (0.75-1.36)	0.98 (0.70-1.38)	0.9011
Multivariate*	1	0.99 (0.74-1.34)	0.96 (0.68-1.35)	0.7725

* HRs were adjusted for age, educational level, body mass index, smoking status, passive smoking during childhood, energy intake, physical activity, gastrointestinal transit.

Conclusion: High adherence to a MD could reduce RA risk in ever-smoking women. Further studies are needed to confirm our findings.

Acknowledgement: We would like to thank the Foundation for Research in Rheumatology (FOREUM) and the French Rheumatology Society (SFR) for their financial support.

Disclosure of Interests: Yann Nguyen: None declared, Carine Salliot: None declared, Amandine gelot: None declared, Juliette Gambaretti: None declared, Xavier Mariette Grant/research support from: Servier, Consultant for: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, UCB Pharma, Marie-Christine Boutron-Ruault: None declared, Raphaële Seror: None declared

DOI: 10.1136/annrheumdis-2019-eular.2900

THU0680

ANTI-PEPTIDYL-ARGININE DEIMINASE 3 AND 4 AUTOANTIBODIES IN A COHORT OF RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE

Boaz Palterer¹, Gianfranco Vitiello¹, Bernardo D'onofrio¹, Emanuele Vivarelli¹, Daniele Cammelli¹, Maria Grazia Giudizi¹, Laura Martinez-Prat², Silvia Casas², Chelsea Bentow², Michael Mahler², Paola Parronchi¹. ¹University of Florence, Department of Clinical and Experimental Medicine, Firenze, Italy; ²Inova Diagnostics, Inc., San Diego, United States of America

Background: Interstitial lung disease (ILD) affects up to 30% of patients with rheumatoid arthritis (RA). Peptidyl-arginine deiminases (PAD) are key enzymes in RA pathogenesis as they are involved in the citrullination of proteins, targets of anti-citrullinated protein antibodies (ACPA). Although RA-ILD significantly contributes to disease burden including mortality, diagnostic and prognostic biomarkers are still lacking.

Objectives: To measure anti-PAD3 and anti-PAD4 antibodies in a cohort of RA and compare their prevalence in patients with and without ILD. To assess the associations of anti-PAD3, anti-PAD4 and ACPA with disease activity, joint erosions, lung involvement and smoking history.

Methods: A total of 71 patients fulfilling the 2010 ACR/EULAR RA Classification Criteria were recruited; the mean age was 63.3 $\pm$ 12.4 and 87% of them were females, 11 (15.5%) of them had been diagnosed with ILD. Demographic, clinical as well as radiological data were retrospectively collected. ILD was defined as usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP) or indeterminate patterns on chest high-resolution computed tomography, according to ATS/ERS guidelines. Particle-based Multi-Analyte Technology (PMAT) (Inova Diagnostics, USA, research use only) was used to measure anti-PAD3 and anti-PAD4 autoantibodies. ACPA IgG were measured by chemiluminescence (QUANTA Flash CCP3, Inova Diagnostics, USA).

Results: Anti-PAD4 levels were correlated with erosive disease ($p=0.043$) and morning stiffness ($p=0.031$). Anti-PAD3 and anti-PAD4 levels were associated to DAS28-ESR at the time of sampling (anti-PAD3, $r=0.34$, $p=0.004$; anti-PAD4, $r=0.34$, $p=0.004$). Anti-PAD4 antibodies were significantly lower in patients with ILD ($p=0.043$). There was no association between anti-PAD4 and smoking, while anti-PAD3 antibodies were higher in non-smokers ($p=0.004$). A strong correlation was found between anti-PAD4 and anti-PAD3 levels ($r=0.73$, $p<0.0001$).

Conclusion: In our cohort, anti-PAD4 antibodies were correlated with joint erosions and RA disease activity, whereas a negative association with ILD was found. Smoking history was not associated with the presence and levels of anti-PAD antibodies. Our data validate the usefulness of anti-PAD4 antibodies as a biomarker for erosive disease. Further studies that take into account relevant confounders like therapy and larger RA-ILD cohorts are needed.

REFERENCES:

- [1] Darrah E, Martinez-Prat L, Mahler M (2019) Clinical Utility of Anti-peptidyl Arginine Deiminase Type 4 Antibodies. J Rheumatol 180905

Disclosure of Interests: Boaz Palterer: None declared, Gianfranco Vitiello: None declared, Bernardo D'onofrio: None declared, Emanuele Vivarelli: None declared, Daniele Cammelli: None declared, Maria Grazia Giudizi: None declared, Laura Martinez-Prat Employee of: Inova Diagnostics (Not pharmaceutical, diagnostics company), Silvia Casas Employee of: Inova Diagnostics, Chelsea Bentow Employee of: INOVA Diagnostics, Michael Mahler Employee of: Inova Diagnostics (Not pharmaceutical, diagnostics company), Paola Parronchi: None declared

DOI: 10.1136/annrheumdis-2019-eular.4781

THU0681

SEXUAL FUNCTION AND REPRODUCTION CAN BE IMPAIRED IN MEN WITH RHEUMATIC DISEASES: A SYSTEMATIC REVIEW

Luis Fernando Perez¹, Bernke Te Winkel², Juan Pablo Carrizales-Luna³, Wichor Bramer⁴, Saskia Vorstenbosch², Eugène van Puijenbroek^{2,5}, Johanna Hazes¹, Radboud Dolhain¹. ¹Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands; ²Netherlands Pharmacovigilance Centre Lareb, 's Hertogenbosch, Netherlands; ³Hospital Universitario Dr José Eleuterio González, Rheumatology, Monterrey, Mexico; ⁴Erasmus Medical Center, Library, Rotterdam, Netherlands; ⁵Groningen Research Institute of Pharmacy, University of Groningen, Pharmacotherapy, -Epidemiology and-economics, Groningen, Netherlands

Background: Sexual function and reproduction are important aspects of quality of life for the majority of men (1,2). In the last decade inflammation has been associated with male factor infertility and sexual dysfunction (3,4). Because many patients with rheumatic diseases have a